Zuranolone — Membership Pricing
Zuranolone is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Zuranolone Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $129.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Zuranolone
Zuranolone is a prescription medication. Ask your doctor if Zuranolone is right for you.
How to Check Zuranolone Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Zuranolone at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Mental Health
What Zuranolone is approved for (FDA label)
ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: June 15, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Zuranolone (FDA label)
WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects [see Warnings and Precautions ( 5.1 , 5.2 )] . Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE [see Warnings and Precautions ( 5.1 )] . WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES See full prescribing information for complete boxed warning. ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after administration. Patients may not be able to assess their own driving competence or the degree of impairment caused by ZURZUVAE ( 5.1 , 5.2 ) .
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Zuranolone (FDA label)
Capsules: 20 mg: light-orange cap, ivory to light-yellow body, printed with “S-217 20mg” on body of capsule in black 25 mg: light-orange cap, light-orange body, printed with “S-217 25mg” on body of capsule in black 30 mg: orange cap, light-orange body, printed with “S-217 30mg” on body of capsule in black Capsules: 20 mg, 25 mg, and 30 mg. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Zuranolone (FDA label)
The following adverse reactions are discussed in more detail in other sections of the labeling: Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities [see Warnings and Precautions ( 5.1 )] Central Nervous System Depressant Effects [see Warnings and Precautions ( 5.2 )] Suicidal Thoughts and Behavior [see Warnings and Precautions ( 5.3 )] Most common adverse reactions (incidence ≥5% and greater than placebo) were somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biogen at 1-844-987-9882 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Zuranolone (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Zuranolone (FDA label)
CNS Depressant Effects: ZURZUVAE can cause CNS depressant effects such as somnolence and confusion. If patients develop CNS depression, consider dosage reduction or discontinuation of ZURZUVAE. ( 5.2 ) Suicidal Thoughts and Behavior: Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose PPD worsens, or who experience emergent suicidal thoughts and behaviors. ( 5.3 ) Embryo-fetal Toxicity: May cause fetal harm. Advise a pregnant woman of the potential risk to an infant exposed to ZURZUVAE in utero.
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Zuranolone (FDA label)
Table 4 displays clinically important drug interactions with ZURZUVAE. Table 4. Clinically Important Drug Interactions with ZURZUVAE CNS Depressant Drugs and Alcohol Clinical Impact Due to additive pharmacological effects, the concomitant use of CNS depressant drugs, including alcohol, may increase impairment of psychomotor performance or CNS depressant effects. Management If use with another CNS depressant is unavoidable, consider dosage reduction. Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol [see Warnings and Precautions ( 5.2 )] . Strong CYP3A4 Inhibitors Clinical Impact Concomitant use of ZURZUVAE with a strong CYP3A4 inhibitor increases the exposure of zuranolone [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of ZURZUVAE-associated adverse reactions.
Source: FDA prescribing information (DailyMed). Set ID: f18e53b0-d0bb-422d-8de7-ab64b7292b29. SPL document ID: 4473196a-b991-4580-b3d4-dbe24f8fe414. Label effective date: June 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.